| Background Cardiovascular disease(CVD) remains the chief cause of death in the world. CVD made up 16.7 million, or 29.2% of total global deaths according to World Health Report 2003. By 2010, CVD will be the leading cause of death in developing countries. Atherosclerosis is the principal cause of this disease, which is a chronic, systemic, and diffuse disease. Rupture of an atherosclerotic plaque exposes its highly procoagulant content to the circulating blood; thereby, tissue factor(TF) initiates thrombus formation and related complications such as acute coronary syndrome. In addition to its well-established role in coagulation, TF participates in other cellular processes. It is involved in migration and proliferation of vascular smooth muscle cells. Previous studies have suggested that elevated levels of TF were observed in patients with cardiovascular risk factors such as hypertension, diabetes, dyslipidemia, and smoking as well as in those with acute coronary syndromes. Therefore, Inhibition of TF action appears to be an attractive target for the treatment of cardiovascular diseases. Macrophages are a major original source of tissue factor in plaques. Statins are inhibitors of the rate-limiting step of cellular cholesterol synthesis. Thiazolidinediones...
|
PDF Full Text Request